| Literature DB >> 35542513 |
Mohamed M El-Wekil1, Hassan Refat H Ali1, Adel A Marzouk2, Ramadan Ali3.
Abstract
An innovative spectrofluorometric method was developed for the analysis of a recently FDA approved anti-hepatitis C velpatasvir (VELP). The developed method was relied on dispersive solid phase extraction (dSPE) using synergistic effect of reduced graphene oxide (RGO) and cobalt hydroxide nanoparticles (CHNPs) in addition to cloud point extraction (CPE) using polyethylene glycol 6000 (PEG 6000) as non-ionic surfactant. This method combines the merits of preconcentration and interferences elimination achieved by dSPE and CPE, respectively. All relevant parameters such as surfactant concentration, ionic strength, pH, incubation time and others were thoroughly investigated and optimized. Fluorometric detection of VELP was carried out at excitation wavelength of 350 nm and emission wavelength of 415 nm. Under the optimum conditions, a linear calibration curve was achieved in the range of 0.5-45 ng mL-1. Limits of detection (LOD) and quantification (LOQ) based on three and ten times the standard deviation of the blank were 0.040 and 0.112 ng mL-1, respectively. This method was successfully applied for determination of VELP in real samples such as tablets, human plasma and urine samples with good recoveries. This journal is © The Royal Society of Chemistry.Entities:
Year: 2018 PMID: 35542513 PMCID: PMC9079717 DOI: 10.1039/c7ra13719b
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 3.361
Fig. 1The emission spectra of Blank (a), 30 ng mL−1 VELP after RGO/CPE (b) and (c) 30 ng mL−1 VELP after RGO/CHNF/CPE.
Fig. 2SEM of RGO (A) and RGO/CHNPs (B) with particle size distribution inset, Raman spectrum of RGO (C), Raman spectra of RGO and CHNPs (D), FTIR of GO, RGO and RGO/CHNPs (E) while (F) is EDX of RGO/CHNPs.
Fig. 4(A) The influence of pH and (B) Influence of different buffers on fluorescence intensity of 30 ng mL−1 of VELP.
Fig. 3(A) The influence of different electrolytes and (B) Influence of Na2SO4 concentration on fluorescence intensity of 30 ng mL−1 of VELP.
Fig. 5The fluorescence spectra for different concentrations of VELP after CPE and the corresponding calibration curve in the range of 0.5–45.0 ng mL−1.
Quantitative parameters for the analysis of VELP by the proposed method and comparison with other reported methods
| Method | Linearity range (ng mL−1) | LOQ (ng mL−1) | LOD (ng mL−1) | Reference |
|---|---|---|---|---|
| RP-HPLC | 25–150 × 103 | 8.3 × 103 | 2.74 × 103 |
|
| 5–25 × 103 | 2.4 × 103 | 0.8 × 103 |
| |
| 1–60 × 103 | 0.003 × 103 | 0.001 × 103 |
| |
| Spectrofluorometry | 0.5–45.0 | 0.12 | 0.04 | This work |
Determination of VELP in pure form and tablets using proposed and reference methods
| Form | Concentration | Mean % recovery ± SD |
|
| |
|---|---|---|---|---|---|
| Proposed method | Reference method[ | ||||
| Pure | 30 | 99.7 ± 1.14 | 98.5 ± 1.23 | 1.85 | 1.12 |
| 40 | 98.9 ± 1.55 | 100.23 ± 1.65 | 1.76 | 1.33 | |
| Epclusa® tablets | 30 | 97.84 ± 1.35 | 98.02 ± 1.44 | 1.22 | 1.11 |
| 40 | 98.13 ± 1.54 | 98.56 ± 1.36 | 1.64 | 1.02 | |
Concentration was calculated in ng mL−1 and μg mL−1 for proposed and reference method, respectively.
Average of five replicates.
Theoretical values at 95% confidence limit: t = 2.31, F = 6.39.
Accuracy and precision of the proposed method for the analysis of VELP in spiked human plasma and urine
| Urine samples | Plasma samples | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Inter-day assay ( | Intra-day assay ( | Concentration (ng mL−1) | Inter-day assay ( | Intra-day assay ( | Concentration (ng mL−1) | ||||
| Precision (%RSD) | Accuracy (%) | Precision (%RSD) | Accuracy (%) | Precision (%RSD) | Accuracy (%) | Precision (%RSD) | Accuracy (%) | ||
| 1.18 | 98.6 | 1.59 | 97.1 | 5 | 1.57 | 97.2 | 1.67 | 99.2 | 3 |
| 1.16 | 100.7 | 1.62 | 99.4 | 10 | 1.35 | 99.6 | 1.34 | 99.3 | 10 |
| 1.75 | 98.1 | 1.64 | 101.5 | 30 | 1.45 | 99.6 | 1.32 | 98.5 | 20 |
Effect of interfering species on the determination of 10 ng mL−1 VELP
| Interfering species (X) | Tolerance ratios (X)/VELP |
|---|---|
|
| |
| Glucose | 5000 |
| Lactose | 4000 |
|
| |
| Ascorbic acid | 10 000 |
| Uric acid | 7000 |
| Dopamine | 8000 |
|
| |
| Sofosbuvir | 1200 |
| Omeprazole | 5000 |
| Pantoprazole | 5000 |
| Ribavirin | 4000 |
|
| |
| Ca2+, Mg2+ | 15 000 |
| Cu2+, Zn2+ | 14 000 |
| Na+, K+ | 20 000 |
| C2O42- | 15 000 |
| SO42−, CO32- | 12 000 |
Determination of VELP in plasma and urine samples by the proposed method
| Sample | Standard added (ng mL−1) | Standard found (ng mL−1) (±SD | % Recovery |
|---|---|---|---|
| Plasma | — | 14.45 ± 0.21 | — |
| 5 | 19.24 ± 0.32 | 98.92 | |
| 10 | 23.95 ± 0.42 | 97.96 | |
| Urine | 5 | 5.15 ± 0.09 | 103.00 |
| 10 | 10.05 ± 0.18 | 100.50 |
Average of five replicates.
Analyzed after 3 hours of collection.